These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 27763866)

  • 1. Vitiligo Induced by Specific Immunotherapy With Grass Pollen: The Koebner Phenomenon.
    Rodríguez-Jiménez B; Muñoz-García E; Veza Perdomo S; González Herrada C; Kindelán-Recarte C; Domínguez-Ortega J
    J Investig Allergol Clin Immunol; 2016; 26(5):331-332. PubMed ID: 27763866
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of allergy-related symptoms with sensitisation to common allergens in an adult European population.
    Arshad SH; Karmaus W; Matthews S; Mealy B; Dean T; Frischer T; Tsitoura S; Bojarskas J; Kuehr J; Forster J;
    J Investig Allergol Clin Immunol; 2001; 11(2):94-102. PubMed ID: 11642579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant pollen allergens from Dactylis glomerata: preliminary evidence that human IgE cross-reactivity between Dac g II and Lol p I/II is increased following grass pollen immunotherapy.
    Roberts AM; Van Ree R; Cardy SM; Bevan LJ; Walker MR
    Immunology; 1992 Jul; 76(3):389-96. PubMed ID: 1526648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin E and G antibody profiles to grass pollen allergens during a short course of sublingual immunotherapy.
    Aberer W; Hawranek T; Reider N; Schuster C; Sturm G; Kränke B
    J Investig Allergol Clin Immunol; 2007; 17(3):131-6. PubMed ID: 17583098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.
    Wahn U; Tabar A; Kuna P; Halken S; Montagut A; de Beaumont O; Le Gall M;
    J Allergy Clin Immunol; 2009 Jan; 123(1):160-166.e3. PubMed ID: 19046761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allergens. Heterogeneity of molecular sensitization profiles in grass pollen allergy--implications for immunotherapy?
    Darsow U; Brockow K; Pfab F; Jakob T; Petersson CJ; Borres MP; Ring J; Behrendt H; Huss-Marp J
    Clin Exp Allergy; 2014; 44(5):778-86. PubMed ID: 24598010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
    Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
    Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy.
    Bousquet J; Braquemond P; Feinberg J; Guerin B; Maasch H; Michel FB
    Ann Allergy; 1986 Jun; 56(6):456-9. PubMed ID: 3717711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule.
    Metz-Favre C; Linhart B; Focke-Tejkl M; Purohit A; de Blay F; Valenta R; Pauli G
    J Allergy Clin Immunol; 2007 Aug; 120(2):315-21. PubMed ID: 17512042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grass pollen counts, air pollution levels and allergic rhinitis severity.
    Annesi-Maesano I; Rouve S; Desqueyroux H; Jankovski R; Klossek JM; Thibaudon M; Demoly P; Didier A
    Int Arch Allergy Immunol; 2012; 158(4):397-404. PubMed ID: 22487690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
    Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
    Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.
    Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M
    J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of allergy to new aeroallergens during specific immunotherapy (SIT) in grass pollen sensitive patients.
    Obtulowicz K; Cichocka-Jarosz E
    Allerg Immunol (Paris); 1998 Oct; 30(8):250-4. PubMed ID: 9846194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral reactions to sublingual immunotherapy: a bioptic study.
    Marcucci F; Sensi L; Incorvaia C; Di Cara G; Moingeon P; Frati F
    Allergy; 2007 Dec; 62(12):1475-7. PubMed ID: 17983387
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
    Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
    Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
    J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
    Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
    J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
    Malling HJ; Lund L; Ipsen H; Poulsen L
    J Investig Allergol Clin Immunol; 2006; 16(3):162-8. PubMed ID: 16784009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis.
    Dahl R; Roberts G; de Blic J; Canonica GW; Kleine-Tebbe J; Nolte H; Lawton S; Nelson HS
    Allergy Asthma Proc; 2016; 37(2):92-104. PubMed ID: 26802643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.